Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.

ABSTRACT:

SUBMITTER: Reich DS 

PROVIDER: S-EPMC8434816 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature